Joshua H. Bilenker

Josh Bilenker has a diverse work experience in the biotechnology and medical field. Josh is currently the CEO and Co-Founder of Treeline Biosciences since April 2021. Prior to this, they served as the Chief Executive Officer at Loxo Oncology at Lilly from December 2019 to January 2021. Before joining Loxo Oncology at Lilly, they were an Operating Partner at Aisling Capital from 2006 to 2019. Josh Bilenker also founded and served as the Chief Executive Officer of Loxo Oncology, a cancer-focused biotechnology company, from July 2013 to February 2019, during which time the company was acquired by Eli Lilly and Company. Josh started their career as a Medical Officer at FDA in 2004 and earlier worked as a Resident and Fellow at the Hospital of the University of Pennsylvania from 1999 to 2004.

Josh Bilenker earned an AB in English from Princeton University from 1990 to 1994. Following that, they obtained an MD from The Johns Hopkins University School of Medicine, specializing in Medicine, from 1995 to 1999.